TaiRuikang's Liver Cancer Drug Completes First Patient Enrollment in China Phase 2 Trial; New Generation ADC Payload Gains International Attention

TaiRuikang, a Taiwanese new drug company, has initiated its Phase 2 clinical trial for its core anti-cancer drug, CVM-1118, in China. The first six patients have been enrolled, indicating rapid progress in clinical execution and patient recruitment, aligning with the company's expectations.

This Phase 2 trial is a single-arm, open-label study designed to assess the efficacy, safety, and pharmacokinetics of CVM-1118 when used alongside the PD-1 immune checkpoint inhibitor "Tislelizumab" and transarterial chemoembolization (TACE). The trial aims to recruit 40 patients with unresectable, non-metastatic intermediate liver cancer across multiple Chinese medical centers, having started enrollment in April and expecting to complete it within a year.

“

The Phase 2 clinical trial for our core anti-cancer drug CVM-1118 in China has successfully commenced, with the first six patients enrolled, demonstrating rapid entry into the clinical execution phase and good patient recruitment efficiency.

Beyond CVM-1118, TaiRuikang is focusing on antibody-drug conjugates (ADCs), a rapidly growing area in cancer drug development. The company has developed a novel payload, CVM-1125, which differs from current market standards by inducing tumor cell apoptosis and inhibiting metabolic pathways. This innovative mechanism aims to provide a differentiated approach to cancer treatment.

“

The enrollment of the first patient cohort in the China liver cancer clinical trial is an important milestone for the global clinical development of CVM-1118. Based on the current trial progress, the first patient is expected to undergo their initial tumor imaging assessment starting at the end of July.

TaiRuikang's chairman, Lin Qun, highlighted the positive reception of CVM-1118's research and clinical progress at the BIO International Convention in the U.S., where the company engaged with over twenty international pharmaceutical firms. The successful enrollment of the first patient cohort in China marks a significant milestone for CVM-1118's global development. The first patient is scheduled for their initial tumor imaging assessment by the end of July.

The company's ADC platform, particularly its innovative mechanism and potential to overcome drug resistance, has garnered significant attention from major multinational pharmaceutical companies and leading ADC development teams. Following the BIO convention, TaiRuikang has signed confidentiality agreements with three potential partners and is currently in the technical data review and exchange phase, aiming to accelerate international licensing and collaboration opportunities for its payload platform.

“

Our ADC platform attracted high attention from many major multinational pharmaceutical companies and top global ADC development teams at the BIO International Convention this year, with its innovative mechanism of action and potential to overcome drug resistance becoming key points for collaboration evaluation.